Literature DB >> 11313409

Uncoordinated HLA-D gene expression in a RFXANK-defective patient with MHC class II deficiency.

A M Lennon-Duménil1, M R Barbouche, J Vedrenne, T Prod'Homme, M Béjaoui, S Ghariani, D Charron, M Fellous, K Dellagi, C Alcaïde-Loridan.   

Abstract

We describe the analysis of a patient, JER, presenting classical immunological features of MHC class II deficiency. Unexpectedly, some HLA transcripts (HLA-DRA, HLA-DQA, and HLA-DMA) were found to be expressed in the JER cell line at nearly wild-type levels, while HLA-DPA and the HLA-D beta-chain transcripts were not detected. Gene reporter experiments confirmed the differential transcriptional activities driven by the HLA-D promoters in the JER cells. A defect in RFXANK was first suggested by genetic complementation analyses, then assessed with the demonstration of a homozygous mutation affecting a splice donor site downstream exon 4 of RFXANK. Because the severe deletion of the resulting protein cannot account for the expression of certain HLA-D genes, minor alternative transcripts of the RFXANK gene were analyzed. We thereby showed the existence of a transcript lacking exon 4, encoding a 28-aa-deleted protein that retains a transcriptional activity. Altogether, we characterize a new type of mutation in the RFXANK gene in a MHC class II-defective patient leading to an uncoordinated expression of the HLA-D genes, and propose that this phenotype is ensured by severely limited amounts of an active, although truncated RFXANK protein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313409     DOI: 10.4049/jimmunol.166.9.5681

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population.

Authors:  Hamid Naamane; Ouafaa El Maataoui; Fatima Ailal; Abdelhamid Barakat; Siham Bennani; Jilali Najib; Mohammed Hassar; Rachid Saile; Ahmed Aziz Bousfiha
Journal:  Eur J Pediatr       Date:  2010-04-23       Impact factor: 3.183

2.  Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.

Authors:  Thomas Prod'homme; Benjamin Dekel; Giovanna Barbieri; Barbara Lisowska-Grospierre; Rina Katz; Dominique Charron; Catherine Alcaide-Loridan; Shimon Pollack
Journal:  Immunogenetics       Date:  2003-10-22       Impact factor: 2.846

3.  Clinical, immunological and genetic features in eleven Algerian patients with major histocompatibility complex class II expression deficiency.

Authors:  Réda Djidjik; Nesrine Messaoudani; Azzedine Tahiat; Yanis Meddour; Samia Chaib; Aziz Atek; Mohammed Elmokhtar Khiari; Nafissa Keltoum Benhalla; Leila Smati; Abdelatif Bensenouci; Mourad Baghriche; Mohammed Ghaffor
Journal:  Allergy Asthma Clin Immunol       Date:  2012-08-03       Impact factor: 3.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.